

The Pharma Jukebox

VOLUME 1, ISSUE 2 | JULY, 2011 NEWSLETTER

*Compassion is more potent than passion,
Empathy is deeper than sympathy,
Compassion and Empathy
go beyond oneself and hence
is the mark of a True Leader.*

- Vishal Jajodia
CEO

From the editor's desk :

Aasha means "hope" in the Indian Sanskrit language and that is precisely what Swati Spentose Pvt Ltd wants to create, especially for IC, a debilitating condition that causes immense pain in and around the bladder wall.

Prior research on neglected disease drug development suggested inadequate funding was responsible for relatively few new approvals. The lack of capital makes it difficult for companies to commit typically scarce resources to research and development for neglected tropical diseases.

Through this issue of "The Pharma Jukebox", we intend to create awareness about diagnosis and treatment among the masses on the subject of IC, a disease that very few are aware of. We are bringing you doctor's opinions, patient's testimonials, expert's views and much more.

I am looking forward to receiving your queries, dilemma and thoughts.

Sanaa Jummal
Editor

Feedback At:

Email: pr@spentose.com

Contact Details:
+91- 22- 61505208



"We never fail when we try to do our duty, we always fail when we "neglect" to do it.."

- Robert Baden Powell

Do words like schistosomiasis, lymphatic filariasis, ascariasis, interstitial cystitis ring a bell? If not, then it's not your fault. Most of these diseases have little recognition in industrialized countries, but together they cause fatal outcomes. Neglected diseases, more precisely known as Neglected Tropical Diseases, are a group of contagious diseases widely spread amongst the poorer populations of the world.

Why were these diseases referred to as "neglected"? The ignorance of health officials along with the lack of research and development regarding these diseases is the true answer to this question. Reducing the burden posed by neglected diseases requires increased R&D for new drugs. The net effect is that only 10% of global

R&D resources are directed at like Interstitial Cystitis (IC) and diseases accounting for 90% of the global disease burden. Varicose Veins.

Previously, pharmaceutical companies 'avoided' producing drugs for diseases affecting third world nation, as people there did not have enough money to buy them.

But the scenario has changed after the WHO launched the **Priority Review Voucher** that allows any pharmaceutical company that develops a drug for any of these diseases, an "expedited review of a different drug that would not normally qualify for such consideration". And hence all of these diseases are being targeted for control or elimination due to remarkable scientific breakthroughs and unprecedented corporate philanthropy. For instance, social entrepreneur **Vishal Jajodia** (CEO of Swati Spentose Pvt Ltd) has taken the initiative to do his bit in disease awareness and elimination of neglected diseases

SSPL, a pharmaceutical biotech company with a niche scientific platform of polysaccharides specialization, with one of its lead molecule Pentosan Polysulphate Sodium, from their wide range of therapeutic compounds, is well suited to serve this space for neglected diseases of Interstitial Cystitis. For the entire basket of such products kindly contact us.

For further details on IC, visit us at

www.comfora.in

www.comforachemist.in

www.spentose.in

"Be the Change, You want to See". With seven long years dedicated to Pentosan, Mr. Vishal Jajodia had already envisioned the future.


SOMETHING ABOUT THE COMPANY:

Swati Spentose Pvt Ltd, is a subsidiary of the 40 year old Euresian group.

Swati Spentose has established unique-cutting edge technology platforms in the development of Polysaccharides bio-generics, in collaboration with world renowned research platforms like Mt Sinai School of Medicine and clinicians and scientists world over.

The key therapeutic areas of Swati Spentose include urology, chronic progressive vascular disease and diabetes among others.

Our Basket of Finished Dosages:



- **Anesthetic:**
Anthacaine (Lidocaine)- Vial, Injection, Gel, Spray
- **Anti-Inflammatory:**
Dflam (Dimethyl sulphoxide) - Vial, Gel, Cream

For a complete information on Finished Dosages contact

fd@spentose.com

- **Urology:**
 - I. Comfora (Pentosan Polysulfate sodium)- Capsules
 - II. Dutride T (Dutasteride & Tamsulosin HCl)- Capsules
 - III. Dutride (Dutasteride)- Capsules
 - IV. Terod (Tolterodine Tartrate) - Tablets
 - V. Finflow (Finasteride)- Tablets
 - VI. Tamysin (Tamsulosin)- Tablets

We offer following API's from USFDA, EDQM, UKMCA, TGA Australia, MCC-South Africa approvable site :

- Pentosan Polysulfate sodium
- Dextran Salts
- Hydroxyl Ethyl Starch
- Lidocaine HCl / Base
- Meloxicam
- Phenytoin Base / Sodium

For further information contact : api@spentose.com



SWATI SPENTOSE PVT. LTD.

114, Marine Chambers,
11, New Marine Lines,
Mumbai-400 020, India.

Tel-0091-22-66332427
Fax-0091-22-22071955

For more information visit us at : www.spentose.com

Or Drop in a mail at communications@spentose.com

Or Give us a call at the number mentioned to the left